Alpha Teknova (TKNO) Aktienübersicht
Alpha Teknova, Inc. produziert wichtige Reagenzien für die Entdeckung, Entwicklung und Vermarktung neuartiger Therapien, Impfstoffe und molekularer Diagnostika in den Vereinigten Staaten und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 1/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
TKNO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeAlpha Teknova, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$3.83 |
| 52-Wochen-Hoch | US$7.36 |
| 52-Wochen-Tief | US$1.91 |
| Beta | 0.47 |
| 1 Monat Veränderung | 35.82% |
| 3 Monate Veränderung | 83.25% |
| 1 Jahr Veränderung | -45.75% |
| 3 Jahre Veränderung | 94.42% |
| 5 Jahre Veränderung | n/a |
| Veränderung seit IPO | -84.68% |
Aktuelle Nachrichten und Updates
Analyst Estimates: Here's What Brokers Think Of Alpha Teknova, Inc. (NASDAQ:TKNO) After Its First-Quarter Report
Alpha Teknova, Inc. ( NASDAQ:TKNO ) defied analyst predictions to release its quarterly results, which were ahead of...
TKNO: Long Term Revenue Guidance Will Support Future Upside Potential
Analysts have adjusted their price target on Alpha Teknova to $7.00 per share from $7.00, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. What's in the News Alpha Teknova issued revenue guidance for the fiscal year ending December 31, 2026, with an expected total revenue range of $42 million to $44 million (company guidance).TKNO: Long Term Revenue Guidance And Higher P/E Will Support Future Upside
Analysts have adjusted their price target on Alpha Teknova to $7.00 from $7.00, reflecting updated views on discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Alpha Teknova issued revenue guidance for the fiscal year ending December 31, 2026, indicating an expected total revenue range of $42 million to $44 million.Recent updates
Analyst Estimates: Here's What Brokers Think Of Alpha Teknova, Inc. (NASDAQ:TKNO) After Its First-Quarter Report
Alpha Teknova, Inc. ( NASDAQ:TKNO ) defied analyst predictions to release its quarterly results, which were ahead of...TKNO: Long Term Revenue Guidance Will Support Future Upside Potential
Analysts have adjusted their price target on Alpha Teknova to $7.00 per share from $7.00, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. What's in the News Alpha Teknova issued revenue guidance for the fiscal year ending December 31, 2026, with an expected total revenue range of $42 million to $44 million (company guidance).TKNO: Long Term Revenue Guidance And Higher P/E Will Support Future Upside
Analysts have adjusted their price target on Alpha Teknova to $7.00 from $7.00, reflecting updated views on discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Alpha Teknova issued revenue guidance for the fiscal year ending December 31, 2026, indicating an expected total revenue range of $42 million to $44 million.TKNO: Long Term Revenue Guidance Will Support Future Upside Potential
Analysts have adjusted their price target on Alpha Teknova to $7.00 from $7, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that leave their fair value view essentially unchanged. What's in the News Alpha Teknova issued revenue guidance for the fiscal year ending December 31, 2026, indicating expected total revenue in a range of $42 million to $44 million.TKNO: Updated Revenue Outlook Will Support Future Upside Potential
Analysts have trimmed their price target on Alpha Teknova to $7.00 from $7 as they factor in updated assumptions for the discount rate, revenue growth, profit margin and future P/E. Their view remains broadly aligned with prior estimates while they fine tune the model inputs.TKNO: Steady Fair Value Anchor Will Support Future Upside Potential
Analysts have trimmed their price target on Alpha Teknova to $7.00 from $7 as they adjust assumptions around discount rates, revenue growth, profit margins, and future P/E. This reflects updated views on the company’s risk profile and earnings potential.TKNO: Steady Fair Value Anchor Will Support Future Upside Potential
Narrative Update on Alpha Teknova Analysts have kept their fair value estimate for Alpha Teknova broadly steady at about $7.00. They explain that modest tweaks to assumptions, such as a slightly higher discount rate, small adjustments to revenue growth and profit margin outlooks, and a marginally lower future P/E, leave their overall price target view essentially unchanged.TKNO: Earnings Guidance And Tuck In Deals Will Support Future Upside
Analysts have nudged their price target on Alpha Teknova slightly higher, citing updated assumptions around discount rates, revenue growth of about 17.6% and a future P/E near 46.1x to support a modestly refined fair value estimate of about $7.00 per share. What's in the News Alpha Teknova reiterated earnings guidance for the fiscal year ending December 31, 2025, with total revenue still expected in the range of $39 million to $42 million.Alpha Teknova, Inc.'s (NASDAQ:TKNO) Share Price Is Still Matching Investor Opinion Despite 29% Slump
Unfortunately for some shareholders, the Alpha Teknova, Inc. ( NASDAQ:TKNO ) share price has dived 29% in the last...TKNO: Earnings Guidance And Tuck In Deals Will Drive Future Upside
Analysts have modestly adjusted their price target on Alpha Teknova, citing an updated fair value of $7.00, a slightly higher discount rate, revised revenue growth expectations to 17.46%, a small change in the assumed profit margin, and a lower future P/E estimate of 46.25x. What's in the News Alpha Teknova reiterated earnings guidance for the fiscal year ending December 31, 2025, with expected total revenue in a range of $39 million to $42 million.TKNO: Earnings Guidance And Tuck In Deals Will Support Future Upside
Narrative Update: Alpha Teknova Analysts have modestly raised their price target on Alpha Teknova by approximately $1.00 per share, reflecting slightly higher assumptions for long term revenue growth and profit margins. This is partially offset by a marginally higher discount rate and a small reduction in projected future P E multiples.TKNO: Earnings Guidance And M&A Efforts Will Support Future Upside Potential
Analysts have trimmed their price target for Alpha Teknova from 8 dollars to 7 dollars, citing slightly slower expected revenue growth and a higher perceived discount rate, despite modestly better margin and valuation assumptions. What's in the News Reiterated 2025 earnings guidance, maintaining projected total revenue in the range of 39 million dollars to 42 million dollars for the year ending December 31, 2025 (company guidance).Earnings Update: Here's Why Analysts Just Lifted Their Alpha Teknova, Inc. (NASDAQ:TKNO) Price Target To US$10.00
Alpha Teknova, Inc. ( NASDAQ:TKNO ) just released its quarterly report and things are looking bullish. Results overall...Alpha Teknova, Inc.'s (NASDAQ:TKNO) P/S Is Still On The Mark Following 27% Share Price Bounce
Alpha Teknova, Inc. ( NASDAQ:TKNO ) shares have had a really impressive month, gaining 27% after a shaky period...Alpha Teknova, Inc.'s (NASDAQ:TKNO) 26% Cheaper Price Remains In Tune With Revenues
To the annoyance of some shareholders, Alpha Teknova, Inc. ( NASDAQ:TKNO ) shares are down a considerable 26% in the...Shareholders Will Probably Not Have Any Issues With Alpha Teknova, Inc.'s (NASDAQ:TKNO) CEO Compensation
Key Insights Alpha Teknova will host its Annual General Meeting on 17th of June CEO Stephen Gunstream's total...
Acquisitions And Collaborations Will Expand Cell And Gene Therapy Portfolio
Expansion through collaborations and acquisitions aims to boost top-line growth, margins, and financial stability amidst anticipated market rebound.Alpha Teknova, Inc. (NASDAQ:TKNO) Just Reported And Analysts Have Been Lifting Their Price Targets
Alpha Teknova, Inc. ( NASDAQ:TKNO ) shareholders are probably feeling a little disappointed, since its shares fell 9.3...Alpha Teknova, Inc. (NASDAQ:TKNO) Stocks Pounded By 31% But Not Lagging Industry On Growth Or Pricing
Alpha Teknova, Inc. ( NASDAQ:TKNO ) shareholders won't be pleased to see that the share price has had a very rough...Calculating The Fair Value Of Alpha Teknova, Inc. (NASDAQ:TKNO)
Key Insights The projected fair value for Alpha Teknova is US$8.71 based on 2 Stage Free Cash Flow to Equity With...Revenues Tell The Story For Alpha Teknova, Inc. (NASDAQ:TKNO) As Its Stock Soars 28%
Despite an already strong run, Alpha Teknova, Inc. ( NASDAQ:TKNO ) shares have been powering on, with a gain of 28% in...Revenues Tell The Story For Alpha Teknova, Inc. (NASDAQ:TKNO) As Its Stock Soars 42%
Despite an already strong run, Alpha Teknova, Inc. ( NASDAQ:TKNO ) shares have been powering on, with a gain of 42% in...Alpha Teknova, Inc. (NASDAQ:TKNO) Might Not Be As Mispriced As It Looks After Plunging 30%
Unfortunately for some shareholders, the Alpha Teknova, Inc. ( NASDAQ:TKNO ) share price has dived 30% in the last...Not Many Are Piling Into Alpha Teknova, Inc. (NASDAQ:TKNO) Stock Yet As It Plummets 25%
To the annoyance of some shareholders, Alpha Teknova, Inc. ( NASDAQ:TKNO ) shares are down a considerable 25% in the...Health Check: How Prudently Does Alpha Teknova (NASDAQ:TKNO) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Some Analysts Just Cut Their Alpha Teknova, Inc. (NASDAQ:TKNO) Estimates
Market forces rained on the parade of Alpha Teknova, Inc. ( NASDAQ:TKNO ) shareholders today, when the analysts...Take Care Before Jumping Onto Alpha Teknova, Inc. (NASDAQ:TKNO) Even Though It's 30% Cheaper
Unfortunately for some shareholders, the Alpha Teknova, Inc. ( NASDAQ:TKNO ) share price has dived 30% in the last...Alpha Teknova, Inc. (NASDAQ:TKNO) Just Reported, And Analysts Assigned A US$23.00 Price Target
As you might know, Alpha Teknova, Inc. ( NASDAQ:TKNO ) just kicked off its latest quarterly results with some very...Aktionärsrenditen
| TKNO | US Life Sciences | US Markt | |
|---|---|---|---|
| 7D | 6.7% | 1.9% | 2.2% |
| 1Y | -45.8% | 7.9% | 31.1% |
Rendite im Vergleich zur Industrie: TKNO unter dem Niveau der Branche US Life Sciences , die im vergangenen Jahr eine Rendite von 7.9% erzielte.
Rendite vs. Markt: TKNO hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 31.1 erzielte.
Preisvolatilität
| TKNO volatility | |
|---|---|
| TKNO Average Weekly Movement | 12.8% |
| Life Sciences Industry Average Movement | 8.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: Der Aktienkurs von TKNO war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.
Volatilität im Zeitverlauf: TKNODie wöchentliche Volatilität (13%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1996 | 158 | Stephen Gunstream | www.teknova.com |
Alpha Teknova, Inc. produziert wichtige Reagenzien für die Entdeckung, Entwicklung und Vermarktung neuartiger Therapien, Impfstoffe und molekularer Diagnostika in den Vereinigten Staaten und international. Zu den Hauptprodukten des Unternehmens gehören vorgegossene Medienplatten für Zellwachstum und Klonierung, flüssige mikrobielle Kulturmedien und Ergänzungen für die Zellexpansion sowie molekularbiologische Reagenzien für die Probenmanipulation, Resuspension und Reinigung. Das Unternehmen bietet Lab Essentials an, die chemische Formulierungen für die biologische Forschung und die Entdeckung von Arzneimitteln liefern, sowie klinische Lösungen, ein kundenspezifisches Produkt, das bei der Entwicklung und Herstellung von Proteintherapien, Gentherapien, mRNA-Impfstoffen und Diagnosekits verwendet wird.
Alpha Teknova, Inc.'s Grundlagenzusammenfassung
| TKNO grundlegende Statistiken | |
|---|---|
| Marktanteil | US$205.34m |
| Gewinn(TTM) | -US$17.17m |
| Umsatz(TTM) | US$41.80m |
Ist TKNO zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| TKNO Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$41.80m |
| Kosten der Einnahmen | US$27.58m |
| Bruttogewinn | US$14.22m |
| Sonstige Ausgaben | US$31.39m |
| Gewinn | -US$17.17m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.32 |
| Bruttomarge | 34.01% |
| Nettogewinnspanne | -41.07% |
| Schulden/Eigenkapital-Verhältnis | 20.3% |
Wie hat sich TKNO auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/11 12:39 |
| Aktienkurs zum Tagesende | 2026/05/08 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Alpha Teknova, Inc. wird von 7 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Mark Massaro | BTIG |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Paul Knight | KeyBanc Capital Markets Inc. |